A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia (NCT07255846) | Clinical Trial Compass
WithdrawnPhase 1
A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
Stopped: This decision is based solely on internal company prioritization and resource allocation considerations. No patients have been enrolled or dosed in this study and no clinical data have been generated.
United States0Started 2025-12-15
Plain-language summary
This is a Phase 1a/1b, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of TER-1754 (a novel AKT1 inhibitor) in patients with HHT.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection.
* A clinical diagnosis of HHT as defined by the Curaçao criteria
* Baseline (1-month) ESS ≥ 4
* ECOG ≤ 2
* Anemia or parental iron infusion of at least 500 mg or transfusion of at least 2 units of RBCs within the preceding 24 weeks.
* Adequate bone marrow function
* Adequate renal function
* Adequate hepatic function
Exclusion Criteria:
* Prior nonresponse or loss of response to an agent that inhibits AKT1 and/or AKT2 as the primary mechanism of action.
* Diagnosis of DM requiring insulin treatment
* Known significant bleeding sources other than nasal, GI, or menstrual/ uterine
* Known underlying hypoproliferative anemia or clinically significant hemolytic anemia
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Phase 1a: Safety and Tolerability of TER-1754
Timeframe: up to 48 weeks
2
Phase 1a: Maximum Tolerated Dose (MTD) and/or Maximum Administrated Dose (MAD) of TER-1754
Timeframe: 28 days
3
Phase 1b - Evaluate the Change from baseline in epistaxis and symptom-related clinical activity scores at Week 24